中国自主研发全新靶向抗癌药造福非小细胞肺癌患者 - 2019年04月11日

A domestically developed drug targeting one type of lung cancer is expected to complete clinical trials before the end of year and then receive approval for use among patients soon afterward, say experts from Shanghai Chest Hospital, which is leading the trials.
So far there are no drugs specifically targeting patients with MET exon 14 skipping mutation. This mutation is found in 3 percent of lung cancer patients.
“Both Chinese and Western medical experts are conducting research targeting this mutation and our clinical trial of the new targeted medicine has received considerable attention from the international medical community,” said Dr Lu Shun from Shanghai Chest Hospital. Lu is also leading research on the drug with assistance from 33 other hospitals in China.